Video: FDA's TAVI panel in review with Dr. Michael Gibson

Justine Varieur Cadet | | Cardiovascular Business | Interventional Cardiology
Click to play
Video: Justine Cadet speaks with C. Michael Gibson, MD
Interventional Cardiologist
Beth Israel Deaconess Medical Center
Boston, Mass.
BOSTON--Justine Cadet from Cardiovascular Business sat down with C. Michael Gibson, MD, interventional cardiologist at the Beth Israel Deaconess Medical Center in Boston, to discuss the FDA’s Circulatory System Devices Panel, which convened July 20 in Bethesda, Md., and recommended approval of the Sapien transcatheter heart valve (Edwards Lifesciences), based on the results of the Cohort B of the PARTNER trial.

The discussion traversed such topics as the changes to the requested indication, the safety considerations, the final vote and the post-approval studies.

Justine Varieur Cadet

Related Content

Key takeaways from ACC.25: Advances in cardiovascular science
New TAVR research explores adverse outcomes, disease progression in patients with asymptomatic severe AS
Dapagliflozin improves outcomes for elderly TAVR patients with heart failure
Bringing state-of-the-art healthcare to Florida heart patients
Cardiologists make case against routine interventions for asymptomatic severe AS
First comprehensive T-TEER resource examines best practices for tricuspid valve repair

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.